GENE logo

GENE Stock Overview

Profile

Full Name:

Genetic Technologies Limited

Sector:

Healthcare

Industry:

Diagnostics & Research

Country:

Australia

IPO:

September 6, 2005

Indexes:

Not included

Website:

http://genetype.com

Description:

GENE (Genetic Technologies Limited) is a biotechnology company that focuses on developing genetic testing and analysis services. They provide innovative solutions for health and wellness, helping individuals understand their genetic information to make informed decisions about their health and lifestyle.

Key Details

Price

$0.77

Market Cap

$3.71 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$5.02 M(-14.02% YoY)

Annual EPS

-$0.02(+23.50% YoY)

PE Ratio

-

Annual ROE

-182.95%

Annual Debt To Equity

0.35

Beta

0.21

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Jul 28, 2022

Recent annual earnings:

Jul 28, 2022
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Aug 14, 2024

Analyst ratings

Recent major analysts updates

Nov 25, 20 Ladenburg Thalmann
Sell
Nov 16, 12 Ladenburg Thalmann
Sell

Screeners with GENE included

Growing Shares Outstanding
Stocks cheaper than 1 dollar
Stocks below SMA 200
Healthcare sector
All stocks
NASDAQ Listed Companies
Small cap stocks
Stocks with low beta
Diagnostics & Research industry
NASDAQ earnings calendar

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$0.77
GENE price is $0.77

Price All-time High

$1385.00
GENE price is currently -99.94% below its historical high of $1385.00

Price Analysts Target

-
GENE price consensus analysts' forecast is unknown

Price Most Recent Change

0%
GENE {parameterFullLabel} has remained unchanged on Mar 7, 2025

Price YTD Change

0%
GENE {parameterFullLabel} has remained unchanged since January 1st

Price 3-Year Change

-91.95%
GENE price is down -91.95% over the past 3 years

Market cap

Market Cap

$3.71 M
GENE market capitalization is $3.71 million

Market Cap 3-Year Change

-87.32%
GENE market capitalization is down -87.32% over the past 3 years

Market Cap All-time High

$179.22 M
GENE market capitalization is currently -97.93% below its historical high of $179.22 million

Market Cap Sector Rank

10.45%
GENE market capitalization is higher than 10.45% of companies in Healthcare sector

Technical

Beta

0.21
GENE beta is 0.21

200-day SMA

$0.96
GENE price is currently -20.08% below its 200-day simple moving average

14-day RSI

50.00
GENE 14-day relative strength index is 50.00

30-day Relative Volume

-
GENE 30-day relative volume value is unknown

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$5.02 M
GENE annual revenue is $5.02 million

Annual Revenue Analysts Estimate

-
GENE annual revenue consensus analysts' forecast is unknown

Annual Revenue 1-Year Change

-14.02%
GENE annual revenue is down -14.02% year-on-year

Annual Revenue Sector Rank

22.08%
GENE annual revenue is higher than 22.08% of companies in Healthcare sector

Profit

Annual Gross Profit

$2.56 M
GENE annual gross profit is $2.56 million

Annual Gross Margin

50.94%
GENE annual gross profit margin is 50.94%

Annual Operating Profit

-$8.00 M
GENE annual operating income is -$8.00 million

Annual Operating Margin

-159.30%
GENE annual operating profit margin is -159.30%

Annual Net Income

-$7.88 M
GENE annual net profit is -$7.88 million

Annual Net Margin

-156.78%
GENE annual net profit margin is -156.78%

EPS

Annual EPS

-$0.02
GENE annual earnings per share is -$0.02

Annual EPS Analysts Estimate

-
GENE annual earnings per share consensus analysts' forecast is unknown

Annual EPS 1-Year Change

+23.5%
GENE annual earnings per share is up +23.5% year-on-year

Annual EPS Sector Rank

82.25%
GENE annual earnings per share is higher than 82.25% of companies in Healthcare sector

ROA & ROE

Annual ROA

-112.80%
GENE annual return on assets is -112.80%

Annual ROE

-182.95%
GENE annual return on equity is -182.95%

EBIT & EBITDA

Annual EBIT

-$7.84 M
GENE annual earnings before interest & taxes is -$7.84 million

Annual EBITDA

-$7.49 M
GENE annual EBITDA is -$7.49 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
GENE price to earnings ratio value is unknown

PE Ratio Sector Rank

-
GENE price to earnings ratio is unknown

PB Ratio

PB Ratio

3.03
GENE price to book ratio is 3.03

PB Ratio Sector Rank

70.43%
GENE price to book ratio is higher than 70.43% of companies in Healthcare sector

PS Ratio

PS Ratio

-
GENE price to sales ratio value is unknown

PS Ratio Sector Rank

-
GENE price to sales ratio is unknown

Enterprise value

Enterprise Value

$3.61 M
GENE enterprise value is $3.61 million

Enterprise Value Sector Rank

16.93%
GENE enterprise value is higher than 16.93% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-
GENE EV/EBITDA value is unknown

EV/EBITDA Sector Rank

-
GENE EV/EBITDA is unknown

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

0.88
GENE annual current ratio is 0.88

Annual Quick Ratio

0.83
GENE annual quick ratio is 0.83

Leverage

Annual Debt To Equity

0.35
GENE annual debt to equity ratio is 0.35

Annual Interest Coverage Ratio

-232.08
GENE annual interest coverage ratio is -232.08

Risk & Stability

Piotroski F-Score

-
GENE piotroski f-score value is unknown

Altman Z-Score

-42.03
GENE altman z-score is -42.03

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$4.14 M
GENE annual total assets is $4.14 million

Annual Non Current Assets

$1.67 M
GENE annual long term assets is $1.67 million

Annual Current Assets

$2.47 M
GENE annual total current assets is $2.47 million

Annual Cash & Cash Equivalents

$682.20 K
GENE annual cash & cash equivalents is $682.20 thousand

Equity

Annual Book Value

$1.22 M
GENE annual book value is $1.22 million

Annual Working Capital

-$334.30 K
GENE annual working capital is -$334.30 thousand

Liabilities

Annual Total Liabilities

$2.91 M
GENE annual total liabilities is $2.91 million

Annual Total Long Term Liabilities

$107.40 K
GENE annual total long term liabilities is $107.40 thousand

Annual Current Liabilities

$2.80 M
GENE annual total current liabilities is $2.80 million

Annual Accounts Payable

$974.60 K
GENE annual accounts payable is $974.60 thousand

Debt

Annual Total Debt

$585.00 K
GENE annual total debt is $585.00 thousand

Annual Total Debt 1-Year Change

+65.86%
GENE annual total debt is up +65.86% year-on-year

Annual Long Term Debt

$15.30 K
GENE annual long term debt is $15.30 thousand

Annual Short Term Debt

$569.70 K
GENE annual short term debt is $569.70 thousand

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$13.03 M
GENE annual total expenses is $13.03 million

Annual Operating Expenses

$10.56 M
GENE annual total operating expenses is $10.56 million

Annual Cost Of Goods Sold

$2.47 M
GENE annual cost of goods sold is $2.47 million

Annual SGA

$8.41 M
GENE annual SGA is $8.41 million

Annual D&A

-
GENE annual depreciation & amortization value is unknown

Annual Interest Expense

$33.80 K
GENE annual interest expense is $33.80 thousand

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-
GENE annual cash flow from operations value is unknown

Annual CFO 1-Year Change

-
GENE annual cash flow from operations 1-year change is unknown

Annual CFI

$75.30 K
GENE annual cash flow from investing activities is $75.30 thousand

Annual CFI 1-Year Change

+135.87%
GENE annual cash flow from investing activities is up +135.87% year-on-year

Annual CFF

$1.85 M
GENE annual cash flow from financing activities is $1.85 million

Annual CFF 1-Year Change

-53.55%
GENE annual cash flow from financing activities is down -53.55% year-on-year

Free CashFlow

Annual FCF

-
GENE annual free cash flow value is unknown

Annual FCF 1-Year Change

-
GENE annual free cash flow 1-year change is unknown

CAPEX

Annual CAPEX

$21.60 K
GENE annual capital expenditures is $21.60 thousand

Annual CAPEX 1-Year Change

+83.05%
GENE annual capital expenditures is up +83.05% year-on-year

Institutional Ownership

Similar stocks

PBM logo
Psyence Biomedical (PBM)
XYLO logo
Xylo Technologies (XYLO)
APVO logo
Aptevo Therapeutics (APVO)
Syra Health Corp Class A (SYRA)
GCTK logo
GlucoTrack (GCTK)
TTOO logo
T2 Biosystems (TTOO)
TOVX logo
Theriva Biologics (TOVX)
NCNA logo
NuCana (NCNA)
SNPX logo
Synaptogenix (SNPX)

FAQ

  • What is the ticker symbol for Genetic Technologies Limited?
  • Does Genetic Technologies Limited pay dividends?
  • What sector is Genetic Technologies Limited in?
  • What industry is Genetic Technologies Limited in?
  • What country is Genetic Technologies Limited based in?
  • When did Genetic Technologies Limited go public?
  • Is Genetic Technologies Limited in the S&P 500?
  • Is Genetic Technologies Limited in the NASDAQ 100?
  • Is Genetic Technologies Limited in the Dow Jones?
  • When was Genetic Technologies Limited's last earnings report?
  • When does Genetic Technologies Limited report earnings?

What is the ticker symbol for Genetic Technologies Limited?

The ticker symbol for Genetic Technologies Limited is NASDAQ:GENE

Does Genetic Technologies Limited pay dividends?

No, Genetic Technologies Limited does not pay dividends

What sector is Genetic Technologies Limited in?

Genetic Technologies Limited is in the Healthcare sector

What industry is Genetic Technologies Limited in?

Genetic Technologies Limited is in the Diagnostics & Research industry

What country is Genetic Technologies Limited based in?

Genetic Technologies Limited is headquartered in Australia

When did Genetic Technologies Limited go public?

Genetic Technologies Limited's initial public offering (IPO) was on September 6, 2005

Is Genetic Technologies Limited in the S&P 500?

No, Genetic Technologies Limited is not included in the S&P 500 index

Is Genetic Technologies Limited in the NASDAQ 100?

No, Genetic Technologies Limited is not included in the NASDAQ 100 index

Is Genetic Technologies Limited in the Dow Jones?

No, Genetic Technologies Limited is not included in the Dow Jones index

When was Genetic Technologies Limited's last earnings report?

Genetic Technologies Limited's most recent earnings report was on Jul 28, 2022

When does Genetic Technologies Limited report earnings?

The date for Genetic Technologies Limited's next earnings report has not been announced yet